Xeris Biopharma Holdings, Inc. XERS

What this company does

Xeris Biopharma offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis. Recorlev, approved in 2022, treats Cushing's syndrome, a condition resulting from sustained, elevated levels of cortisol in the body that affects approximately 25,000 people in the United States, of whom approximately two-thirds are cured by surgery; it has received orphan drug exclusivity status in the United States through December 30, 2028 and patent protection through 2040. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia, indicated for use in pediatric and adult patients with diabetes age two years and above and administered in two steps. Gvoke is available in three presentation types: Gvoke HypoPen, an auto-injector; Gvoke PFS, a pre-filled syringe; and Gvoke Kit, a pre-filled vial and administration syringe. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. It is developing XP-8121, described as the first and only once-weekly subcutaneous injection of levothyroxine for the treatment of hypothyroidism. As of December 31, 2025, it had 435 full-time employees in the United States, of whom 216 were primarily engaged in sales and marketing, 169 in general administration, and 50 in product development and research. It was incorporated under the laws of the State of Delaware in 2021, and its principal offices are located at 1375 West Fulton Street, Chicago, Illinois.

Written from the business description in Xeris Biopharma Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.